ROSEN, LEADING TRIAL ATTORNEYS, Encourages Lifecore Biomedical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LFCR

Core Viewpoint - Lifecore Biomedical, Inc. is facing a class action lawsuit due to alleged false and misleading statements regarding its financial reporting and internal controls during the class period from October 7, 2020, to March 19, 2024 [1][5]. Group 1: Class Action Details - The Rosen Law Firm is reminding investors who purchased Lifecore securities during the class period of the September 27, 2024, deadline to become a lead plaintiff in the class action [1][3]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6]. Group 2: Allegations Against Lifecore - The lawsuit claims that Lifecore had deficient internal controls over financial reporting, leading to inaccurate financial statements that required restatement [5]. - It is alleged that Lifecore's remediation efforts regarding these deficiencies were ineffective, impairing its ability to file periodic reports with the SEC in compliance with NASDAQ requirements [5]. - The lawsuit asserts that Lifecore's financial position and prospects were materially overstated, resulting in misleading public statements [5]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, enhancing the firm's credibility in handling such cases [4].